Shares in Oxford Nanopore Technologies rebounded almost to 125p today after its new CEO recently started work.
Francis Van Parys (pictured) is now leading the FTSE 250 MedTech, which is eyeing profitability after reporting its results for 2025 last week. He has taken over from founder Gordon Sanghera.
Oxford Nanopore reported revenues of £223.9 million, up 22.2% year-on-year, while adjusted EBITDA losses shrank 31.2% to £86.7m. Actual losses shrank 1% to £145.2m.
The firm reaffirmed its commitment to reach adjusted EBITDA breakeven in FY27 and become cash flow positive in FY28.
This morning the DNA sequencing specialist also announced a collaboration with ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals.
They have together launched the world’s first GMP-validated adventitious viral agent detection test based on Oxford Nanopore sequencing. Designed for use in regulated biopharmaceutical quality control environments, this process is designed to ensure biologics medicines are free from viral contamination.
At 119p – writing at 3.30pm – shares in Oxford Nanopore remain up 1.5% today.
Oxford Nanopore floated in 2021 with a price of 615p and topped 700p before a gradual decline. They have lost a third of their value in the last six months and 7% in the year to date despite a brief rise to 172p in January.
Van Parys, who joined from Danaher-owned diagnostics firm Radiometer, brings more than 20 years of senior life sciences leadership experience, while Sanghera will remain in an advisory role through to early 2027 to support the transition.
Sanghera has led the University of Oxford spinout since its founding in 2005, overseeing its IPO, entry into the FTSE 250 and growth to a market capitalisation of around £1.2 billion today.
The group remains well capitalised with £302.8m in cash, cash equivalents and other liquid investments as at 31st December 2025 (FY24: £403.8m).
Oxford Nanopore featured in more than 4,000 peer-reviewed papers published in 2025 – making it 20,000 to date – which it says demonstrates the utility of its benefits and traction in scientific research, spanning cancer, human genetics and infectious disease.
Last year the group launched patent proceedings against MGI Australia: it says MGI has conceded that its Cyclone SEQ WT02 infringes four of Oxford Nanopore’s Australian patents.
A trial has been set for 2027 at which MGI’s remaining defences will be adjudicated.
Separately, in the UK Oxford Nanopore has issued proceedings in the High Court alleging trade secrets infringement, breach of confidence and breach of contract against MGI/ BGI entities.